transduced HSCs
endogenous affected HSCs
proliferation of homed HSCs
reduced number of corrected HSCs
increased CXCR4 levels
CXCR4 haploinsufficiency
HBB gene
MODULATING CXCR4 EXPRESSION β-thalassemias
expression levels
β-globin gene
HSC gene therapy
chemokine receptor CXCR4
HEMATOPOIETIC STEM CELL- BASED GENE THERAPY OUTCOME
inefficient gene correction
therapeutic levels of engraftment
SCD
hand
conditioning toxicity
innovative LV-based strategy
sickle cell disease
broad therapeutic benefit
allogeneic transplantation of hematopoietic stem cells
terms of homing
engraftment efficiencies
increased BM repopulating capacity
autologous transplantation
Alternative strategies
high disease burden
milder conditioning regimen
major hurdle
competition
bone marrow
mediated introduction
lentiviral vector
treatment
functional copy
diseases amenable
production
curative option
restricted availability of compatible donors
abnormal variant
patients
different approaches
competitive advantage
mutations
LVs
defective synthesis
hemoglobin
Thanks
clinical data
fact
migration
addition
proposal